A new prognostic model predicts prostate cancer-specific mortality risk more accurately than existing biopsy calculators, validated through a study involving over 200,000 veterans. This model, derived from the PLCO Cancer Screening Trial, addresses significant gaps in decision-making for the 10 million PSA tests conducted annually by utilizing competing risks and time-to-event predictions. Developed by Dr. Patrick Lewicki's team at the University of Michigan, it aims to better inform patient screening strategies and improve outcomes in prostate cancer management.
1. New prognostic model predicts prostate cancer-specific mortality risk. 2. AUC of 78% in external validation cohort. 3. Developed from the PLCO Cancer Screening Trial data. 4. Incorporates competing risks for other-cause mortality. 5. Clinically relevant threshold for screening discontinuation set at 0.5% risk. 6. Useful in stratifying patients at PSA screening point. 7. Aims to improve outcomes in prostate cancer management.
Listen Tab content
